ORIGINAL RESEARCH article
Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study
- 1Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel VUB, Brussels, Belgium
- 2Department of Public Health, Vrije Universiteit Brussel, Brussels, Belgium
- 3Division of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa
- 4Associazione Sclerosi Tuberosa ONLUS, Milan, Italy
- 5European Tuberous Sclerosis Complex Association, In den Birken, Dattein, Germany
- 6Association Sclérose Tubéreuse de Bourneville, Gradignan, France
- 7TSA Tuberous Sclerosis Association, Nottingham, United Kingdom
- 8Research and Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russia
- 9SPS Pediatrična Klinika, Ljubljana, Slovenia
- 10Hôpital Louis Pradel, Claude Bernard University Lyon 1, Lyon, France
- 11Tor Vergata University Hospital, Rome, Italy
- 12Karolinska University Hospital, Stockholm, Sweden
- 13Novartis Farma S.p.A., Origgio, Italy
- 14Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
- 15Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Affiliated Partner of the ERN EpiCARE, Vienna, Austria
- 16Vivantes-Klinikum Neukölln, Berlin, Germany
- 17Department of Child Neurology, Medical University of Warsaw, Warsaw, Poland
- 18Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
- 19The Tuberous Sclerosis Multidisciplinary Management Clinic, Sydney Children's Hospital, Randwick, NSW, Australia
- 20Hospital Universitari Vall d'Hebron, Barcelona, Spain
- 21Institute of Biomedicine (IBIOMED), University of Leon, León, Spain
- 22Department of Pediatric Neurology, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France
- 23Institute of Child Health, University College London, London, United Kingdom
- 24Department of Pediatrics, Peking University People's Hospital (PKUPH), Beijing, China
- 25Tallinn Children Hospital, Tallinn, Estonia
- 26Klinikverbund Kempten-Oberallgäu gGmbH, Kempten, Germany
- 27Novartis Healthcare Pvt Ltd, Hyderabad, India
- 28National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan
- 29Department of Genetics, CHU-Hôpital Nord, Saint Etienne, France
- 30St. Sophia Children's Hospital, Athens, Greece
- 31University Medical Center, Utrecht, Netherlands
- 32Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Centre, St Georges University of London, London, United Kingdom
Research on tuberous sclerosis complex (TSC) to date has focused mainly on the physical manifestations of the disease. In contrast, the psychosocial impact of TSC has received far less attention. The aim of this study was therefore to examine the impact of TSC on health, quality of life (QoL), and psychosocial well-being of individuals with TSC and their families. Questionnaires with disease-specific questions on burden of illness (BOI) and validated QoL questionnaires were used. After completion of additional informed consent, we included 143 individuals who participated in the TOSCA (TuberOus SClerosis registry to increase disease Awareness) study. Our results highlighted the substantial burden of TSC on the personal lives of individuals with TSC and their families. Nearly half of the patients experienced negative progress in their education or career due to TSC (42.1%), as well as many of their caregivers (17.6% employed; 58.8% unemployed). Most caregivers (76.5%) indicated that TSC affected family life, and social and working relationships. Further, well-coordinated care was lacking: a smooth transition from pediatric to adult care was mentioned by only 36.8% of adult patients, and financial, social, and psychological support in 21.1, 0, and 7.9%, respectively. In addition, the moderate rates of pain/discomfort (35%) and anxiety/depression (43.4%) reported across all ages and levels of disease demonstrate the high BOI and low QoL in this vulnerable population.
Tuberous sclerosis complex (TSC) is a multi-system genetic disorder with a global incidence of 1 per 6,000–10,000 live births. Over a million people are estimated to be affected worldwide (1). It is characterised by growth of benign tumours in various organs throughout the body, including the brain, kidney, lungs, and skin (2). It is also associated with behavioural, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties, grouped under the umbrella term TAND (TSC-Associated Neuropsychiatric Disorders) (3, 4). The clinical presentation of TSC manifestations is complex (5–8). Its natural course varies between individuals, with symptoms occurring at variable ages and severity ranging from very mild to severe, which may even lead to death. Furthermore, individuals with TSC are expected to have lifelong follow-up care to ensure the early detection of potentially life-threatening complications. The diverse clinical presentation represents significant disease, healthcare, and treatment burden (9).
To date, the majority of TSC research has concentrated on the pathophysiology, epidemiology, diagnosis, and treatment of the condition (10). Relatively little has been done to evaluate the impact of TSC on the quality of life (QoL) and social well-being of individuals with TSC and their families. A number of researchers have focused on the burden of specific aspects of TSC, such as epilepsy, subependymal giant cell astrocytoma (SEGA), facial angiofibroma, and renal angiomyolipoma (8, 9, 11–14). Others have evaluated the impact of specific treatments on QoL such as following epilepsy surgery (15), or have studied specific groups such as the impact on adult caregivers (10, 16). A retrospective study that evaluated parents of 99 children with TSC showed that about 50% reported clinically significant parental stress. The stress was related to the presence of current seizures, a history of psychiatric diagnosis, intellectual disability, and/or behavioural problems in the children (17). A web-based United Kingdom (UK) survey of individuals with TSC and their caregivers showed significantly lower health state utility values (HSUVs) compared with the general population reference value for the UK value set of the three-level version of the EuroQol-5D (EQ-5D-3L). This indicates substantial impairment in individuals with TSC (18). Zöllner et al. performed a systematic review on the burden of illness (BOI) in TSC and included 33 articles published up to October 2019, only 14 of which addressed QoL (19). We sought to assess the impact of TSC on the lives of individuals or their caregivers in terms of BOI and QoL, using a combination of ancillary disease-specific questions on BOI and validated QoL questionnaires in seven European countries.
TOSCA, a natural history registry in TSC, was conducted in 170 sites across 31 countries worldwide. A detailed description of the methods of the TOSCA study has been provided previously (20). The registry consists of a “core” section and six “petals” or “research projects”. Here, we present findings from one of the research projects focusing on BOI and QoL in individuals with TSC.
Selection of countries participating in this research project was based on the availability of the validated QoL questionnaires in the primary language used in that country. Based on this criterion, TSC individuals of any age from seven European countries were eligible for this specific research project, after signing an additional consent form.
Measuring Burden of Illness
All enrolled individuals were asked to complete a set of ancillary questions addressing social care needs (circumstances of living arrangements, financial, social, and psychological support, and information sources), healthcare needs (health insurance, medical care and level of satisfaction, genetic testing, and genetic counselling), impact on education and employment, impact on family, and transition from paediatric to adult care (Supplementary Material). These ancillary questions were developed by patient representatives, who were part of the TOSCA Working Committee in collaboration with the TSC patient associations. Draft questionnaires were reviewed by two caregivers for clarity and comprehensiveness. When individuals were unable to complete the questionnaires by themselves, caregivers were asked to complete the proxy version of the questionnaires (caregiver report).
Measuring Quality of Life
For evaluating QoL, validated questionnaires in local languages were administered to individuals with TSC/caregivers who participated in this research project. These included the following: (1) EuroQol-5D (EQ-5D), a self-complete questionnaire for adults (age, ≥18 years); the EQ-5D proxy version 1 was completed by the caregiver for children or adolescents for adults who were unable to complete the report by themselves; (2) QoL in Epilepsy Inventory-31-Problems (QOLIE-31)-P for adults (age, ≥18 years) with epilepsy, completed by the individuals themselves; (3) QoL in Childhood Epilepsy (QOLCE) for children <10 years old with epilepsy (completed by caregivers); (4) QoL in Epilepsy Inventory for Adolescents-48 (QOLIE-AD-48) for children aged 11–17 years with epilepsy, completed by the subjects themselves.
Data on QoL and BOI were recorded once (i.e., no follow up requested) before the data cut-off date (10 August, 2017). A copy of the collected paper questionnaires was sent from each clinical site to the clinical research organization (CRO) for data entry in the TOSCA study. Data were then extracted and analysed by the CRO. Responses to the BOI questions and QOL scales were summarised by descriptive statistics (number of responders, mean, standard deviation, median, range, frequency), considering age-based subgroup as children (<11 years), adolescents (age 11 to <18 years) and adults (age ≥18 years).
Individuals with TSC or their caregivers, rated their level of impairment across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has three levels: no problems, some problem and confined to bed. The mean thermometer score for EQ-5D and mean health state score for QOLIE-31-P questionnaire were recorded on a scale from 0 to 100, with 0 being the worst health state imaginable and 100 the best. Furthermore, each patient rated the importance of the seven QOLIE 31-P sub scales (energy, mood, daily activities, cognition, medication effects, seizure worry, and overall quality of life) from one to seven, with one being the most important topic and seven the least important one. The sub-scale scores of QOLIE-31-P questionnaire were the means of the converted item scores multiplied by the distress score. The total QOLIE-31-P score was calculated by dividing the sum of the sub scales by the sum of the distress scores multiplied by 100. If more than half the items in a sub-scale had not answered, the sub-scale was not included in the total score. For each sub scale of QOLCE, the answer for each item was converted to a 0 to 100 point score, where high scores reflect the highest level of functioning.
Hundred fouty three individuals (88 children and adolescents, and 55 adults) from seven European countries were enrolled in this research project as part of the TOSCA study (Table 1). The mean time since initial diagnosis of TSC was 13.5 years (median, 11.2 years; range, 1.6–43.5). Of the 143 individuals enrolled, 67 (28 adults) had epilepsy (46.9%). The mean duration of epilepsy was 16.6 years (median, 12.8 years; range, 2.7–55.4).
Burden of Illness: Self-Reported Outcomes
17 adolescents (19.3%; aged between 11 and <18 years) and 38 adults (69.1%) completed the questionnaire independently. Of these, one (5.9%) adolescent and five adults (13.2%) needed extra assistance at home. In most cases, assistance was provided by unpaid caregivers (a family member or friend). 29.4% adolescents and 42.1% of adults felt that assistance and support at home was not sufficient (Table 2). Financial, social, and psychological support was received by 8 (21.1%), 0 (0%), and 3 (7.9%) of adult respondent, respectively.
Nine adolescents (52.9%) and 16 adults (42.1%) had access to public and/or private insurance (Table 3). Although none of the individuals reported that they had to pay extra for private insurance due to TSC, two adults (5.3%) reported that health or any kind of insurance was denied due to TSC. TSC was managed by TSC specialists in 12 adolescents (70.6%) and 28 adults (73.7%). Twenty-nine adults (76.3%) reported that they had access to a TSC clinic when required, while no access to TSC clinics were reported by six adults (15.8%). TSC was managed by more than three physicians in 15 adults (39.5%). Smooth transition from paediatric to adult care was reported by only 14 adults (36.8%). Nearly one fifth of patients were dissatisfied with various aspects of their medical care and nearly 50% were not able to report if their care followed clinical guidelines (Figure 1).
Figure 1. Satisfaction with treatment aspects in (A) Self-reported children, (B) Self-reported adults, (C) Caregiver-reported children, and (D) Caregiver-reported adults.
TSC was reported to have impacted the career/education progress in three adolescents (17.6%; Table 4). Fourteen adolescents (82.4%) were in mainstream education. Six adolescents (35.3%) received additional support in class; no adolescents were home-schooled. Of the 38 adults, 20 (52.6%) were employed and seven were not able to work (4 due to TSC; 3 due to other reasons). Sixteen adults (42.1%) expressed that TSC had affected their career or education in different ways: impact on career progression/promotions (25%), choice of career (25%), loss of employment (31.3%), part-time rather than full-time work (31.3%), or attainment of education level (37.5%).
Burden of Illness: Caregiver-Reported Outcomes
Parents/Caregivers completed the questionnaires for 71 children and adolescents (80.7%; 38 girls and 32 boys) and 17 adults (30.9%; 11 female and 6 male) who were unable to complete the questionnaires by themselves.
Of the 71 caregiver-reported children and adolescents, 20 (28.2%) needed help at home, provided mainly by unpaid caregivers in 80% of cases (Table 2). Of the 17 caregiver-reported adults, one (5.9%) was living alone, two (11.8%) with a partner, and 13 (76.5%) with other family members. Eight (47.1%) individuals needed help with daily activities. About half of the caregiver-reported individuals (50.7% children and adolescents, and 52.9% adults) were in contact with their local TSC associations.
TSC was managed by TSC specialists in 39 (54.9%) caregiver-reported children and adolescents, and 16 (94.1%) caregiver-reported adults (Table 3). Twenty-three caregivers (32.4%) reported that their children and adolescents did not have access to TSC specialist clinics but most caregiver-reported adults (94.1%) did. Most caregiver-reported children and adolescents (80.3%) and caregiver-reported adults (94.1%) received genetic testing for TSC, but genetic counselling was received only by 60.6% of children and adolescents, and 58.8% of adults. None of the six (35.3%) caregiver-reported adults who received private insurance felt that they had to pay extra due to TSC and only one patient (5.9%) reported that health or any kind of insurance was denied due to TSC.
Caregivers have reported that TSC had affected the career or education of their children and adolescents in different ways. These include part-time work rather than full time (53.2%), impact on career progression/promotions (36.2%), choice of career (34.0%), loss of employment (21.2%), impact on educational attainment (6.4%). Of the 17 caregiver-reported adults, only three (17.6%) were employed while 10 (58.8%) were unable to work due to TSC. Ten (83.3%) carer-reported adults reported impact of educational attainment. Relationships of caregivers had been impacted due to child's TSC in 53.5% of cases with impact on the family, social, and working colleague relationships were reported in 29 (40.8%), 36 (50.7%), and 17 (23.9%) cases, respectively. Impact on the family, social and working relationships by TSC condition have been noted in 76.5% of caregiver-reported adults.
Quality of Life (QoL) in TSC
Overall, EQ-5D (or Q-5D proxy version 1) questionnaires were completed for all 143 participants. Difficulty in mobility was reported by 34 individuals (23.8%) and 32 (22.4%) experienced difficulty in self-care. Twenty-six individuals (18.2%) were unable to perform usual activities, fifty individuals (35%) had moderate pain or discomfort and four individuals (2.8%) had extreme pain or discomfort. Sixty-two individuals (43.4%) reported moderate anxiety/depression, while six individuals (4.2%) reported extreme anxiety/depression. Anxiety/depression and pain/discomfort were reported in both self-reported as well as caregiver-reported groups and present in both children and adolescents, and adults (Figure 2). On the thermometer scale of 0–100 (100 being the best state of health imaginable and 0 as worst state imaginable) the mean score was 70.6.
The QOLIE-31-P questionnaire was completed by 24 individuals. The total score of the QOLIE-31-P questionnaire was 71.6 (standard deviation [SD]: ±16.7, Table 5). The mean (±SD) score for different sub-scales were: energy (47.0 ± 27.6), mood (53.4 ± 29.8), daily activities (67.0 ± 33.3), cognition (63.6 ± 37.5), medication effects (56.9 ± 31.5), seizure worry (49.8 ± 31.4), and overall quality of life (53.8 ± 29.1).
The QOLCE questionnaire was completed by 70 caregivers. The mean QOLCE score was 52.3 (SD: ±18.9, Table 5). The mean (±SD) scores of different sub-scales were: QoL (51.5 ± 27.5), physical restrictions (44.6 ± 24.4), energy/fatigue (54.5 ± 22.7), depression (70.7 ± 17.6), anxiety (58.8 ± 20.5), control/helplessness (56.1 ± 20.1), self-esteem (63.9 ± 19.6), attention/concentration (37.5 ± 28.7), memory (54.2 ± 23.8), language (42.1 ± 28.7), other cognitive functions (31.7 ± 29.0), social interactions (53.6 ± 21.7), social activities (63.8 ± 35.5), stigma (66.1 ± 36.4), behaviour (50.5 ± 20.6), and general health (48.5 ± 27.3). The highest score was reported for depression and the lowest for other cognitive functions.
Eight adolescents aged 11–17 years with epilepsy completed the questionnaire. The mean total QOLIE-AD-48 questionnaire score was 74.2 (SD: ±13.9, Table 5). The score of the sub-scales were epilepsy impact (82.7 ± 20.2), memory/concentration (74.1 ± 22.3), physical functioning (83.1 ± 18.1), stigma (81.9 ± 22.2), social support (69.5 ± 22.5), school behaviour (97.7 ± 3.2), attitudes toward epilepsy (30.4 ± 7.6), and health perceptions (61.5 ± 9.9).
This study aimed to evaluate BOI and QoL in children and adolescents, and adults with TSC and their families. BOI focused on social care needs, health (care) needs, and impact of TSC on education, employment, and family life. Individuals' QoL was assessed by means of standardized measures of QoL. To our knowledge, this study represented the most comprehensive and multinational evaluation of BOI and QoL in TSC to date.
Four main findings were highlighted by this study. BOI in families with TSC patients was high, as shown by their experiences of insufficient assistance at home and from social services. Individuals with TSC reported significant use of healthcare services but considered the support from TSC associations and patient organizations as inadequate. Also, the impact of TSC on individuals' education, employment, and social and family life was profound. Regarding quality of life, both children and adolescents, and adults reported moderate-to-severe levels of pain or discomfort and anxiety or depression, which was also indicated by their caregivers.
Individuals with TSC and their families have unmet needs with respect to support from social workers who provide various services, corresponding to previous findings (8). Most services were not available, or not offered or performed properly. Possibly, these professionals were insufficiently aware of the specific needs of individuals with or lack the experience to provide appropriate support. Another explanation for this unmet need might be difficulty in reaching out to families of individuals with TSC by social workers due to practical reasons, or families of individuals with TSC had personal barriers to seek help. Clearly, our findings underline the urgent need for increased awareness among social services about the importance of early and systematic follow-up of individuals with TSC and their environment (21). When such needs remain unrecognised, family members feel urged to take on various responsibilities and failed to introduce further professional care in a timely manner, preventing optimal guidance with attention to individual goals or preferences.
Individuals with TSC showed various clinical manifestations for which they visited health specialists. Throughout their lives, they made significant use of healthcare services as a result of the regular multidisciplinary medical care indicated for the management of TSC (22). However, the present study showed that high healthcare utilization and followed-up by a TSC specialist or clinic were unrelated to involvement of TSC associations and patient organizations in the individual's care trajectory. Reasons could be that patients were not familiar with them, not convinced of their significance for their own situation or experience sufficient support from their own private network. It was also plausible that these societal partners failed to reach families with TSC in the right way or did not meet their expectations regarding types of support.
The observed lack of appropriate care services was also reflected in differences between individuals in terms of health insurance, and genetic testing, and counselling. These findings indicate a need for revision and standardization of insurance policies for people with TSC or chronic conditions in general, as well as clinical care characterized by a personalized and transparent approach. Despite this imbalance between care need and care provision, individuals in this study reported satisfaction with how their disease was treated and monitored. Furthermore, the transition from paediatric to adult TSC care was an important area of concern (23). Although this phase is generally considered challenging or difficult (24), our results showed a smooth process in almost half of the cases. Transition-enhancing practices such as use of an individual action plan, implementation of a transition protocol and setting up a mixed paediatric-adult team with a transition coordinator might be useful in TSC care (25, 26).
TSC had a strong influence on the education and professional career of affected individuals. Especially in adults, their level of education, choice of career, career progression and promotion, and employment rate were impacted by the disease. Apart from the presence of TSC, other influences, directly or indirectly, related to the illness should be taken into account. Having few professional expectations for the future, being confronted with negative attitudes of colleagues and lacking arrangements to improve working conditions, might all further reduce the patient's opportunities at work (27, 28). The impact of TSC on education was relatively minor in the group of self-reporting adolescents, a finding that is likely biased by their assumed milder phenotype since they were able to fill-out the BOI and QOL questionnaires independently. Previous research showed a higher degree of absenteeism, impaired performance, and lower productivity at school in paediatric patients (28). It seems therefore advisable to guide young patients on study choice and keep track of adults' working life, while listening to expressed questions, concerns, and problems.
TSC has significant effects on the social well-being and family life of both young and adult individuals with TSC. The patients' high dependence on their environment can lead to feelings of disorientation, loneliness, and clinically significant stress levels in patients, but also in family members (10, 17). Our data show the marked effect of TSC on the income, career, and psychological well-being of the individual's family. Therefore, it is essential to identify and approach the sources of such familial distress, which vary according to the patient's personal characteristics, health status, and living environment. Problems in children and adults with TSC such as severe epilepsy and other persistent health problems, neuropsychiatric disorders (TAND) and a lack of support from the family's network can put a heavy burden on the family of individuals with TSC (2, 29, 30). As a result, the family may become isolated as friendships and professional relationships receive less attention (16). However, it has been shown that external support might help building the family's resources, as they can cope better with the multifaceted problems of TSC and regularly shift their attention from the disease to pleasant events and moments in life (10).
With regard to QoL, moderate to severe levels of pain or discomfort and anxiety or depression were reported by individuals with TSC of all ages as well as by their caregivers. In order to achieve a comprehensive view of health-related QoL in individuals with TSC, research suggested to investigate other indicators such as fatigue, emotional stress, and participation (31). In particular, participation is important, as this multidimensional concept captures how the patient's health determines his or her participation in daily life, taking into account functional and intellectual disabilities. Assessing the individual's participation rate in terms of education, social activities, and leisure time is required for the development of interventions, which enable a long life with a good QoL (32). In future studies on BOI and QoL, standardized instruments to measure participation such as questionnaires for patients and carers could be used (33, 34).
When interpreting the results of this study, certain limitations need to be taken into account. Not all patients completed all questionnaires in the study, and only a small subsample of patients from the TOSCA registry enrolled in the present study. Although the information was collected from both individuals who were able to self-report as well as from caregivers of individuals who were unable to self-report, the overall disease severity of the cohort is likely to be milder compared to that of the global TOSCA registry cohort. Only 46.85% of patients in the current study was reported to have epilepsy in contrast to 83.5% in the overall TOSCA cohort (35). Since epilepsy is known to have a major impact on QoL (36), the burden of illness reported here might reflect the impact at the milder end of the spectrum. Furthermore, these subjects were all recruited from clinicians specialized in TSC care. Therefore, the level of care and satisfaction in the general TSC population is likely to be lower.
Although no data on intellectual ability were collected, 65% of children were following mainstream education. Although school systems differ across countries and attending mainstream education does not imply that children have normal intellectual ability, it seems likely that this reflects again a potential bias towards the milder end of the spectrum. The lack of a personal perspective is another limitation of the study. The questionnaire used to measure BOI contained questions that were developed together with families, which ensures a large patient-oriented input. Although no qualitative research was conducted, a short analysis of the questionnaire's open data fields did confirm the quantified BOI (data not shown).
Our study confirms the impact of TSC on education, career and social life of patients, and their families. This disease-specific impact is also reflected in patients' quality of life, including moderate-to-high levels of pain or discomfort and anxiety or depression. Unfortunately, despite families' frequent use of healthcare services, provision of well-organized TSC care is not evident as shown by their experiences of insufficient social support and discontinuous pediatric to adult care trajectories. These difficulties further increase the impact on the different life domains of families living with TSC, who would benefit from better coordinated educational, psychosocial, and medical support.
Data Availability Statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: Novartis supports the publication of scientifically rigorous analysis that is relevant to patient care, regardless of a positive or negative outcome. Qualified external researchers can request access to anonymized patient-level data, respecting patient informed consent, contacting study sponsor authors. The protocol can be accessed through EnCePP portal http://www.encepp.eu/ (EU PAS Register Number EUPAS3247).
The studies involving human participants were reviewed and approved by independent ethics committee/institutional review board for each centre involved in the study (see Supplementary Materials for full list). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.
AJ, EB, MB, PC, MD, JF, MF, CH, SJ, JK, JL, AM, RN, VS, MS, RT, and BZ designing the study, patient accrual, clinical care, data interpretation, drafting, revising, final review, and approval of the manuscript. SV data interpretation, drafting, revising, final review, and approval of the manuscript. PV designing the study, data interpretation, drafting, revising, final review, and approval of the manuscript. CF designing the study, data interpretation, drafting, revising, final review, and approval of the manuscript. CF, GB, TC, VC, FO'C, JQ, YT, and SY designing the study, data interpretation, drafting, revising, final review, and approval of the manuscript. LD'A designing the study, trial management, data collection, data analysis, data interpretation, drafting, revising, final review, and approval of the manuscript. RM designing the study, data analysis, data interpretation, drafting, revising, final review, and approval of the manuscript. SS designing the study, trial statistician, data analysis, data interpretation, drafting, revising, final review, and approval of the manuscript. All authors contributed to the article and approved the submitted version.
The study was funded by Novartis Pharma AG. Novartis has contributed to the study design, data analysis, and the decision to publish. Novartis authors reviewed the draft for submission.
Conflict of Interest
AJ, PV, EB, TC, VC, PC, GB, JK, JF, MF, CF, CH, SJ, RN, FO'C, JQ, MS, RT, MD, JL, AM, SY, MB, and BZ received honoraria and support for the travels from Novartis. VC received personal fees for consulting, lecture fees, and travel from Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, Gilead, GSK, MSD, Novartis, Pfizer, Roche, Sanofi; grants from Actelion, Boehringer Ingelheim, GSK, Pfizer, Roche; personal fees for developing educational material from Boehringer Ingelheim and Roche. PV has been on the study steering group of the EXIST-1, 2, and 3 studies sponsored by Novartis, and co-PI on two investigator-initiated studies part-funded by Novartis. RN received grant support, paid to her institution, from Eisai and lectures fees from Nutricia, Eisai, Advicenne, and GW Pharma. YT received personal fee from Novartis for lecture and for copyright of referential figures from the journals, and received grant from Japanese government for intractable epilepsy research. SJ was partly financed by the EC Seventh Framework Programme (FP7/2007-2013; EPISTOP, grant agreement no. 602391), the Polish Ministerial funds for science (years 2013-2018) for the implementation of international cofinanced project and the grant EPIMARKER of the Polish National Center for Research and Development No STRATEGMED3/306306/4/2016. JK, PC, CH, JL, and JQ received research grant from Novartis. RM, LD'A, and SS are employees of Novartis. This study was funded by Novartis Pharma AG.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
We thank patients and their families, investigators, and staff from all participating sites. The authors thank Manojkumar Patel (Novartis Healthcare PVT Ltd) for providing medical writing support, which was funded by Novartis Pharmaceutical Corporation in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
Japan: Nobuo Shinohara, Shigeo Horie, Masaya Kubota, Jun Tohyama, Katsumi Imai, Mari Kaneda, Hideo Kaneko, Yasushi Uchida, Tomoko Kirino, Shoichi Endo, Yoshikazu Inoue, Katsuhisa Uruno; Turkey: Ayse Serdaroglu, Zuhal Yapici, Banu Anlar, Sakir Altunbasak; Russia: Olga Lvova, Oleg Valeryevich Belyaev, Oleg Agranovich, Elena Vladislavovna Levitina, Yulia Vladimirovna Maksimova, Antonina Karas; China: Yuwu Jiang, Liping Zou, Kaifeng Xu, Yushi Zhang, Guoming Luan, Yuqin Zhang, Yi Wang, Meiling Jin, Dingwei Ye, Weiping Liao, Liemin Zhou, Jie Liu, Jianxiang Liao, Bo YAN, Yanchun Deng, Li Jiang, Zhisheng Liu, Shaoping Huang, Hua Li; Korea: Kijoong Kim; Taiwan: Pei-Lung Chen, Hsiu-Fen Lee, Jeng-Dau Tsai, Ching-Shiang Chi, Chao-Ching Huang; Australia: Kate Riney, Deborah Yates, Patrick Kwan; Thailand: Surachai Likasitwattanakul, Charcrin Nabangchang, Lunliya Thampratankul Krisnachai Chomtho, Kamornwan Katanyuwong, Somjit Sriudomkajorn; South Africa: Jo Wilmshurst; Israel: Reeval Segel, Tal Gilboa, Michal Tzadok, Aviva Fattal- Valevski; Greece: Panagiotis Papathanasopoulos, Antigone Syrigou Papavasiliou, Stylianos Giannakodimos, Stylianos Gatzonis, Evangelos Pavlou, Meropi Tzoufi; Netherlands: A.M.H. Vergeer; Belgium: Marc Dhooghe, Hélène Verhelst, Filip Roelens, Marie Cecile Nassogne, Pierre Defresne, Liesbeth De Waele, Patricia Leroy, Nathalie Demonceau, Benjamin Legros, Patrick Van Bogaert, Berten Ceulemans, Lina Dom; France: Pierre Castelnau, Anne De Saint Martin, Audrey Riquet, Mathieu Milh, Claude Cances, Jean-Michel Pedespan, Dorothee Ville, Agathe Roubertie, Stéphane Auvin, Patrick Berquin, Christian Richelme, Catherine Allaire, Sophie Gueden, Sylvie Nguyen The Tich, Bertrand Godet; Spain: Maria Luz Ruiz Falco Rojas, Jaume Campistol Planas, Antonio Martinez Bermejo, Patricia Smeyers Dura, Susana Roldan Aparicio, Maria Jesus Martinez Gonzalez, Javier Lopez Pison, Manuel Oscar Blanco Barca, Eduardo Lopez Laso, Olga Alonso Luengo, Francisco Javier Aguirre Rodriguez, Ignacio Malaga Dieguez, Ana Camacho Salas, Itxaso Marti Carrera, Eduardo Martinez Salcedo, Maria Eugenia Yoldi Petri, Ramon Cancho Candela; Portugal: Ines da Conceicao Carrilho, Jose Pedro Vieira, José Paulo da Silva Oliveira Monteiro, Miguel Jorge Santos de Oliveira Ferreira Leao, Catarina Sofia Marceano Ribeiro Luis, Carla Pires Mendonca; Lithuania: Milda Endziniene; Latvia: Jurgis Strautmanis; Estonia: Inga Talvik; Italy: Maria Paola Canevini, Antonio Gambardella, Dario Pruna, Salvatore Buono, Elena Fontana, Bernardo Dalla Bernardina; Romania: Carmen Burloiu, Iuliu Stefan Bacos Cosma, Mihaela Adela Vintan, Laura Popescu; Czech Republic: Karel Zitterbart; Slovakia: Jaroslava Payerova, Ladislav Bratsky, Zuzana Zilinska; Austria: Ursula Gruber-Sedlmayr, Matthias Baumann, Edda Haberlandt, Kevin Rostasy, Ekaterina Pataraia; United Kingdom: Frances Elmslie, Clare Ann Johnston, Pamela Crawford; Denmark: Peter Uldall; Sweden: Paul Uvebrant, Olof Rask; Norway: Marit Bjoernvold, Eylert Brodtkorb, Andreas Sloerdahl, Ragnar Solhoff, Martine Sofie Gilje Jaatun; Poland: Marek Mandera, Elzbieta Janina Radzikowska, Mariusz Wysocki; Germany: Michael Fischereder, Gerhard Kurlemann, Bernd Wilken, Adelheid Wiemer-Kruel, Klemens Budde, Klaus Marquard, Markus Knuf, Andreas Hahn, Hans Hartmann, Andreas Merkenschlager, Regina Trollmann.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.00904/full#supplementary-material
3. de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr Neurol. (2015) 52:25–35. doi: 10.1016/j.pediatrneurol.2014.10.004
4. Leclezio L, Jansen A, Whittemore VH, de Vries PJ. Pilot validation of the tuberous sclerosis-associated neuropsychiatric disorders (TAND) checklist. Pediatr Neurol. (2015) 52:16–24. doi: 10.1016/j.pediatrneurol.2014.10.006
5. Kingswood C, Bolton P, Crawford P, Harland C, Johnson SR, Sampson JR, et al. The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the clinical practice research datalink (CPRD). Eur J Paediatr Neurol. (2016) 20:296–308. doi: 10.1016/j.ejpn.2015.11.011
8. Hallett L, Foster T, Liu Z, Blieden M, Valentim J. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr Med Res Opin. (2011) 27:1571–83. doi: 10.1185/03007995.2011.586687
9. Skalicky AM, Rentz AM, Liu Z, Wheless JW, Pelletier CL, Dunn DW, et al. The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. J Child Neurol. (2015) 30:563–9. doi: 10.1177/0883073814523318
10. Graffigna G, Bosio C, Cecchini I. Assisting a child with tuberous sclerosis complex (TSC): a qualitative deep analysis of parents' experience and caring needs. BMJ Open. (2013) 3:e003707. doi: 10.1136/bmjopen-2013-003707
11. Crall C, Valle M, Kapur K, Dies KA, Liang MG, Sahin M, et al. Effect of angiofibromas on quality of life and access to care in tuberous sclerosis patients and their caregivers. Pediatr Dermatol. (2016) 33:518–25. doi: 10.1111/pde.12933
12. Rentz AM, Skalicky AM, Liu Z, Dunn DW, Frost MD, Nakagawa JA, et al. Burden of renal angiomyolipomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. J Patient Rep Outcomes. (2018) 2:30. doi: 10.1186/s41687-018-0055-4
13. Shepherd C, Koepp M, Myland M, Patel K, Miglio C, Siva V, et al. Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy: a retrospective cohort study in the UK clinical practice research datalink (CPRD). BMJ Open. (2017) 7:e015236. doi: 10.1136/bmjopen-2016-015236
14. de Vries PJ, Franz DN, Curatolo P, Nabbout R, Neary M, Herbst F, et al. Measuring health-related quality of life in tuberous sclerosis complex – psychometric evaluation of three instruments in individuals with refractory epilepsy. Front Pharmacol. (2018) 9:964. doi: 10.3389/fphar.2018.00964
15. Roth J, Olasunkanmi A, MacAllister WS, Weil E, Uy CC, Devinsky O, et al. Quality of life following epilepsy surgery for children with tuberous sclerosis complex. Epilepsy Behav. (2011) 20:561–5. doi: 10.1016/j.yebeh.2010.11.003
16. Rentz AM, Skalicky AM, Pashos CL, Liu Z, Magestro M, Pelletier CL, et al. Caring for children with tuberous sclerosis complex: what is the physical and mental health impact on caregivers? J Child Neurol. (2015) 30:1574–81. doi: 10.1177/0883073815575364
17. Kopp CM, Muzykewicz DA, Staley BA, Thiele EA, Pulsifer MB. Behavior problems in children with tuberous sclerosis complex and parental stress. Epilepsy Behav. (2008) 13:505–10. doi: 10.1016/j.yebeh.2008.05.010
18. Tritton T, Bennett B, Brohan E, Grant L, Cooper A, Fladrowski C, et al. Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: a web-based survey. Epilepsy Behav. (2019) 92:213–20. doi: 10.1016/j.yebeh.2018.11.021
19. Zollner JP, Franz DN, Hertzberg C, Nabbout R, Rosenow F, Sauter M, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. (2020) 15:23. doi: 10.1186/s13023-019-1258-3
20. Kingswood JC, Bruzzi P, Curatolo P, de Vries PJ, Fladrowski C, Hertzberg C, et al. TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet J Rare Dis. (2014) 9:182. doi: 10.1186/s13023-014-0182-9
21. Bar C, Ghobeira R, Azzi R, Ville D, Riquet A, Touraine R, et al. Experience of follow-up, quality of life, and transition from pediatric to adult healthcare of patients with tuberous sclerosis complex. Epilepsy Behav. (2019) 96:23–7. doi: 10.1016/j.yebeh.2019.04.027
22. Rentz AM, Skalicky AM, Liu Z, Wheless JW, Dunn DW, Frost MD, et al. Tuberous sclerosis complex: a survey of health care resource use and health burden. Pediatr Neurol. (2015) 52:435–41. doi: 10.1016/j.pediatrneurol.2014.11.013
23. Auvin S, Bissler JJ, Cottin V, Fujimoto A, Hofbauer GFL, Jansen AC, et al. A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a delphi consensus report. Orphanet J Rare Dis. (2019) 14:91. doi: 10.1186/s13023-019-1072-y
24. Both P, Ten Holt L, Mous S, Patist J, Rietman A, Dieleman G, et al. Tuberous sclerosis complex: concerns and needs of patients and parents from the transitional period to adulthood. Epilepsy Behav. (2018) 83:13–21. doi: 10.1016/j.yebeh.2018.03.012
25. Schwartz LA, Tuchman LK, Hobbie WL, Ginsberg JP. A social-ecological model of readiness for transition to adult-oriented care for adolescents and young adults with chronic health conditions. Child Care Health Dev. (2011) 37:883–95. doi: 10.1111/j.1365-2214.2011.01282.x
26. Morsa M, Gagnayre R, Deccache C, Lombrail P. Factors influencing the transition from pediatric to adult care: a scoping review of the literature to conceptualize a relevant education program. Patient Educ Couns. (2017) 100:1796–806. doi: 10.1016/j.pec.2017.05.024
28. Skalicky AM, Rentz AM, Liu Z, Said Q, Nakagawa JA, Frost MD, et al. Economic burden, work, and school productivity in individuals with tuberous sclerosis and their families. J Med Econ. (2018) 21:953–59. doi: 10.1080/13696998.2018.1487447
31. van der Mei SF, Dijkers MP, Heerkens YF. Participation as an outcome measure in psychosocial oncology: content of cancer-specific health-related quality of life instruments. Qual Life Res. (2011) 20:1617–27. doi: 10.1007/s11136-011-9900-0
32. Cerniauskaite M, Quintas R, Boldt C, Raggi A, Cieza A, Bickenbach JE, et al. Systematic literature review on ICF from 2001 to 2009: its use, implementation and operationalisation. Disabil Rehabil. (2011) 33:281–309. doi: 10.3109/09638288.2010.529235
33. Postma S, van Boven K, Ten Napel H, Gerritsen D, Assendelft W, Schers H, et al. The development of an ICF-based questionnaire for patients with chronic conditions in primary care. J Clin Epidemiol. (2018) 103:92–100. doi: 10.1016/j.jclinepi.2018.07.005
34. Ackerley S, Gordon H, Elston A, Crawford L, McPherson K. Assessment of quality of life and participation within an outpatient rehabilitation setting. Disabil Rehabil. (2009) 31:906–13. doi: 10.1080/09638280802356419
35. Kingswood JC, d'Augeres GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. TuberOus SClerosis registry to increase disease awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. (2017) 12:2. doi: 10.1186/s13023-016-0553-5
Keywords: tuberous sclerosis complex, quality of life, burden of illness, epilepsy, TOSCA
Citation: Jansen AC, Vanclooster S, de Vries PJ, Fladrowski C, Beaure d'Augères G, Carter T, Belousova E, Benedik MP, Cottin V, Curatolo P, Dahlin M, D'Amato L, Ferreira JC, Feucht M, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B and Kingswood JC (2020) Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. Front. Neurol. 11:904. doi: 10.3389/fneur.2020.00904
Received: 07 May 2020; Accepted: 14 July 2020;
Published: 28 August 2020.
Edited by:Alessandro Simonati, University of Verona, Italy
Reviewed by:Wang-Tso Lee, National Taiwan University Hospital, Taiwan
Jill Edith Cadwgan, Evelina London Children's Hospital, United Kingdom
Copyright © 2020 Jansen, Vanclooster, de Vries, Fladrowski, Beaure d'Augères, Carter, Belousova, Benedik, Cottin, Curatolo, Dahlin, D'Amato, Ferreira, Feucht, Hertzberg, Jozwiak, Lawson, Macaya, Marques, Nabbout, O'Callaghan, Qin, Sander, Sauter, Shah, Takahashi, Touraine, Youroukos, Zonnenberg and Kingswood. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anna C. Jansen, Anna.Jansen@uzbrussel.be
†Novartis employee at the time of manuscript concept approval